IRON STATUS, ERYTHROPOIETIN, HYPOXIA INDUCTOR FACTORS IN CHILDREN WITH ANEMIA WITH CHRONIC KIDNEY DISEASE
https://doi.org/10.24884/1561-6274-2017-21-6-68-77
Abstract
Objective: to compare the indicators of iron metabolism, the level of hypoxia induced factor (HIF-1α) and erythropoietin (EPO) in children with anemia in CKD Stage 1-5.
Patients and methods: three groups of patients: I – 32 children under dialysis with CKD Stage 1-5 without therapy, II – 18 children up to dialysis CKD Stage 2-5 receiving treatment with iron and ESP, group III – 30 dialysis patients with CKD Stage 3-5 receiving treatment with iron and ESP. Serum levels of EPO and HIF-1α was determined by solid-phase chemiluminescent enzyme-linked immunosorbent assay method (sandwich) using a test system Biomerica EPO ELISA kit to determine the level of HIF-1α, Cloud-Clone Corp.
Results: In the I group, a statistically significant increase in the level of HIF-1α (0,089 ± 0,011ng / ml) was found compared with the mean normal (0,043 ng / ml) (p = 0.0001). In the II group, an increased level of EPO (63,01 ± 14,84 MIU / ml) was found in comparison with normal (17,56 MIU / ml) (p = 0,0088), an increase in HIF-1α (0,138 ± 0,025 ng / ml) compared with normal (0,043 ng / ml) (p = 0.005). A comparative study of EPO and HIF-1α in children with CKD showed a statistically significant increase in EPO and HIF-1α in the II group before dialysis (on therapy) compared to group I before dialysis (without therapy). A correlation between GFR and HIF-1α was established in group II patients.
Conclusion: A direct correlation between the level of GFR and HIF-1α in the blood was revealed in patients of group II with CKD Stage 2-5 before dialysis, receiving preparations of erythropoietin and iron. In the I group, before dialysis (without therapy) and III group of dialysis patients receiving ESP and iron, the binding strength of GFR and HIF-1α is not significant.
About the Authors
E. V. Lysova
Saint-Petersburg State pediatric medical university
Russian Federation
Russian Federation
Lysova Elena - the department of faculty pediatrics.
194100, St-Petersburg, Litovskaya st., 2, (812) 416-52-86N. D. Savenkova
Saint-Petersburg State pediatric medical university
Russian Federation
Russian Federation
Nadezda D. Savenkova - MD, PhD, DMedSci, Prof., Head of department of faculty pediatrics
194100, St-Petersburg, Litovskaya st., 2, (812) 416-52-86
References
1. Hogg RJ, Furth S, Lemley KV et al. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003; 111(6 Pt 1): 1416-1421
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements 2013; 3(1): 1–150
3. Смирнов АВ, Шилов ЕМ, Добронравов ВA и др. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Национальные рекомендации. Нефрология 2012; 16(1): 89-115 [SmirnovAV, ShilovEM, DobronravovVAidr. Nacional’nyerekomendacii. Hronicheskajabolezn’ pochek: osnovnyeprincipyskrininga, diagnostiki, profilaktikiipodhodyklecheniju. Nacional’nye rekomendacii. Nefrologija 2012; 16(1): 89-115]
4. McMurray J, Parfrey PS, Adamson JW et al (KDIGO work group membership). KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney International Supplements 2012; 2(4): 279–335. doi: 10.1038/kisup.2012.37
5. Avner ED, Harmon WE, Niaudet P, Yoshikawa N. Management of Chronic Kidney Disease. In: VanDeVoorde RG, Warady BA. Pediatric Nephrology. Sixth Completely Revised, Updated and Enlarged Edition, Volume 2. Springer-Verlag, Berlin, 2008;1660-1692
6. Atkinson MA, Martz K, Warady BA, Neu AM. Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS. Pediatr Nephrol 2010; 25(9): 1699–1706. doi: 10.1007/s00467-010-1538-6
7. Baracco R, Saadeh S, Valentini R et al. Iron deficiency in children with early chronic kidney disease. Pediatric Nephrol 2011; 26(11): 2077-2080. doi: 10.1007/s00467-011-1946-2
8. Atkinson MA, Pierce CB, Fadrowski JJ et al. Association between common iron store markers and hemoglobin in children with chronic kidney disease. Pediatr Nephrol 2012; 27(12): 2275-2283. doi: 10.1007/s00467-012-2266-x
9. Atkinson MA, Furth SL. Anemia in children with chronic kidney disease. Nat Rev Nephrol 2011; 7(11): 635–641. doi: 10.1038/nrneph.2011.115
10. Hamed EA, El-Abaseri TB, Mohamed AO et al. Hypoxia and oxidative stress markers in pediatric patients undergoing hemodialysis: cross section study. BMC Nephrol 2012; 13: 13-136. doi: 10.1186/1471-2369-13-136
11. Hirakawa Y, Tanaka T, Nangaku M. Renal Hypoxia in CKD; Pathophysiology and Detecting Methods. Front Physiol 2017; 21: 8-99. doi: 10.3389/fphys.2017.00099
12. Nangaku M, Eckardt KU. Hypoxia and the HIF system in kidney disease. J Mol Med 2007; 85(12): 1325–1330. doi: 10.1007/s00109-007-0278-y
13. Kimura K, Iwano M, Higgins DF et al. Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol Renal Physiol 2008; 295(4): 1023-1029. doi: 10.1152/ajprenal.90209.2008
14. Haase VH. Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol 2006; 291(2): 271–281. doi: 10.1152/ajprenal.00071.2006
15. Hung TW, Liou JH, Yeh KT et al. Renal expression of hypoxia inducible factor-1α in patients with chronic kidney disease: a clinicopathologic study from nephrectomized kidneys. Indian J Med Res 2013; 137(1): 102-110
16. Левина АА, Макешова АБ, Мамукова ЮИ и др. Регуляция гомеостаза кислорода. Фактор, индуцированный гипоксией (HIF) и его значение в гомеостазе кислорода. Педиатрия. Журн им. Г.Н. Сперанского 2009; 87(4): 92-97 [LevinaAA, MakeshovaAB, MamukovaJuIidr. Reguljacija gomeostaza kisloroda. Faktor, inducirovannyj gipoksiej (HIF) i ego znachenie v gomeostaze kisloroda. Pediatrija. Zhurnal im. G.N. Speranskogo 2009; 87(4): 92-97]
17. Luo R, Zhang W, Zhao C et al. Elevated Endothelial Hypoxia-Inducible Factor-1α Contributes to Glomerular Injury and Promotes Hypertensive Chronic Kidney Disease. Hypertension 2015; 66(1): 75-84. doi: 10.1161/HYPERTENSIONAHA.115.05578
18. Wang Z, Zhu Q, Li PL. Silencing of hypoxia-inducible factor-1α gene attenuates chronic ischemic renal injury in twokidney, one-clip rats. Am J Physiol Renal Physiol 2014; 306(10): 1236-1242. doi: 10.1152/ajprenal.00673.2013
19. Gupta N, Wish JB. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients with CKD. Am J Kidney Dis 2017; 69(6): 815-826. doi: 10.1053/j.ajkd.2016.12.011
20. Новиков ВЕ, Левченкова ОС. Гипоксией индуцированный фактор как мишень фармакологического воздействия. Обзоры по клинической фармакологии и лекарственной терапии 2013; 11(2): 8-16 [NovikovVE, Levchenkova OS. Gipoksiej inducirovannyj faktor kak mishen' farmakologicheskogo vozdejstvija. Obzory po klinicheskoj farmakologii i lekarstvennoj terapii2013; 11(2): 8-16]
21. Шило ВЮ, Добронравов ВА, Ермоленко ВМ и др. Обновленные Российские Национальные рекомендации по диагностике и лечению анемии при хронической болезни почек в редакции 2014 года. http://www.nephro.ru/content/files/anemiaRussian2014.pdf [ShiloVJu, DobronravovVA, ErmolenkoVMidr. Obnovlennye Rossijskie Nacional’’ nye rekomendacii po diagnostike i lecheniju anemii pri hronicheskoj bolezni pochek vredakcii 2014 goda. http://www.nephro.ru/content/files/anemiaRussian2014.pdf]
22. Hollowell JG, Van Assendelft OW, Gunter EW et al. Hematological and iron-related analytes – reference data for persons aged 1 year and over: United States, 1988–94. Vital Health Stat 2005; 11(247): 1–156
23. Staples AO, Wong CS, Smith JM et al. Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin J Am Soc Nephrol 2009; 4(1): 48–56. doi: 10.2215/CJN.05301107
24. Fadrowski JJ, Pierce CB, Cole SR et al. Hemoglobin decline in children with chronic kidney disease: baseline results from the chronic kidney disease in children prospective cohort study. Clin J Am Soc Nephrol 2008; 3(2): 457–462. doi: 10.2215/CJN.03020707
25. Бородулин ВБ, Бычков ЕН, Протопопов АА и др. Эритропоэтин – маркер хронической болезни почек на доклинической стадии. Фундаментальные исследования 2013; 11-1: 22-26 [BorodulinVB, BychkovEN, ProtopopovAAidr. Jeritropojetin – marker hronicheskoj bolezni pochek na doklinicheskoj stadii. Fundamental’nye issledovanija 2013; 11-1: 22-26]
26. Warady BA, Silverstein DM . Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease. Pediatr Nephrol 2014; 29(9): 1493-1505. doi: 10.1007/s00467-013-2557-x
27. Tanaka T. Expanding roles of the hypoxia-response network in chronic kidney disease. Clin Exp Nephrol 2016; 20(6): 835-844. doi: 10.1007/s10157-016-1241-4
28. Bonomini M, Del Vecchio L, Sirolli V, Locatelli F. New Treatment Approaches for the Anemia of CKD. Am J Kidney Dis 2016; 67(1): 133-142. doi: 10.1053/j.ajkd.2015.06.030
29. Chen N, Qian J, Chen J et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant 2017; 32(8): 1373-1386. doi: 10.1093/ndt/gfx011
30. Besarab A, Provenzano R, Hertel J et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant 2015; 30(10): 1665–1673. doi: 10.1093/ndt/gfv302
31. Provenzano R, Besarab A, Sun C et al. Oral hypoxiainducible factor prolyl hydroxylase inhibitor Roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin J Am Soc Nephrol 2016; 11(6): 982–991. doi: 10.2215/CJN.06890615
32. Лысова ЕВ, Савенкова НД. СAKUT – синдром в этиологической структуре хронической болезни почек у детей и подростков. Нефрология 2017; 21(3): 69-74 [LysovaEV, SavenkovaND. SAKUT – sindrom v jetiologicheskoj strukture hronicheskoj bolezni pochek u detej i podrostkov. Nefrologija 2017; 21(3): 69-74] doi: 10.24884/1561-6274-2017-3-69-74
33. Лысова ЕВ, Савенкова НД. Особенности синдрома анемии при хронической болезни почек у детей (обзор литературы). Нефрология 2014; 18(3): 34-44 [LysovaEV, SavenkovaND. Osobennosti sindroma anemii pri hronicheskoj bolezni pochek u detej (obzorliteratury). Nefrologija 2014; 18(3): 34-44]
34. Лысова ЕВ, Савенкова НД. Лечение синдрома анемии у детей с хронической болезнью почек (обзор литературы). Нефрология 2015; 19(3): 20-31 [LysovaEV, SavenkovaND. Lechenie sindroma anemii u detej s hronicheskoj bolezn'ju pochek (obzorliteratury). Nefrologija 2015; 19(3): 20-31]
35. Добронравов ВА, Смирнов АВ, Безруких АМ и др. Анемия и преддиализные стадии хронической болезни почек: клиническое значение, распространенность и факторы риска. Нефрология 2006; 10(3): 7-13 [Dobronravov VA, Smirnov AV, Bezrukih AM i dr. Anemija i preddializnye stadii hronicheskoj bolezni pochek: klinicheskoe znachenie, rasprostranennost’ i faktory riska. Nefrologija 2006; 10(3): 7-13]
Review
For citations:
Lysova E.V., Savenkova N.D. IRON STATUS, ERYTHROPOIETIN, HYPOXIA INDUCTOR FACTORS IN CHILDREN WITH ANEMIA WITH CHRONIC KIDNEY DISEASE. Nephrology (Saint-Petersburg). 2017;21(6):68-77. (In Russ.) https://doi.org/10.24884/1561-6274-2017-21-6-68-77
Views:
1280
Email this article 